RCEL

+ Watchlist + Portfolio

Avita Medical, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.01
52-Week Range: $3.22 – $12.76
Market Cap: $393.39M
P/E (TTM): —
EPS (TTM): -1.43
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -41.56%
Gross Margin: 81.56%
Operating Margin: -31.59%
Profit Margin: -56.96%
Current Ratio: 0.41
Debt/Equity: —
Total Debt: $48.48M
Free Cash Flow: $-13.35M
Revenue Growth: 17.80%
Earnings Growth: —
Enterprise Value: $430.74M

RCEL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$34.42M	$50.14M	$64.25M	$71.61M
Cost of Revenue	$6.04M	$7.78M	$9.09M	$12.79M
Gross Profit	$28.38M	$42.36M	$55.16M	$58.82M
Research & Development	$13.86M	$20.82M	$20.36M	$20.84M
Selling, General & Admin	$45.24M	$65.63M	$91.39M	$80.51M
Operating Expenses	$55.88M	$85.02M	$111.75M	$101.35M
Operating Income	-$27.50M	-$42.66M	-$56.59M	-$42.53M
EBITDA	-$26.05M	-$33.54M	-$55.30M	-$41.23M
Pretax Income	-$26.63M	-$35.31M	-$61.79M	-$48.58M
Income Tax	$36.00K	$66.00K	$54.00K	$11.00K
Net Income	-$26.66M	-$35.38M	-$61.84M	-$48.59M
Diluted EPS	-1.07	-1.40	-2.39	-1.74
Diluted Shares	25.00M	25.33M	25.88M	27.86M

RCEL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.16M	$22.12M	$14.05M	$10.24M
Receivables	$4.96M	$7.92M	$11.96M	$9.11M
Inventory	$2.13M	$5.60M	$7.27M	$6.93M
Current Assets	$87.46M	$104.01M	$57.00M	$35.49M
Total Assets	$98.26M	$111.64M	$79.71M	$56.39M
Current Liabilities	$10.69M	$13.20M	$20.16M	$62.68M
Long-Term Debt	—	$39.81M	$42.24M	—
Total Debt	$918.00K	$42.41M	$45.98M	$46.05M
Total Liabilities	$13.52M	$62.58M	$75.21M	$73.04M
Retained Earnings	-$262.59M	-$297.97M	-$359.81M	-$408.40M
Shareholders' Equity	$84.74M	$49.06M	$4.50M	-$16.65M
Working Capital	$76.77M	$90.81M	$36.84M	-$27.19M
Net Debt	—	$17.69M	$28.20M	$32.74M

RCEL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$19.09M	-$38.01M	-$48.94M	-$31.20M
Capital Expenditure	-$525.00K	-$1.45M	-$9.33M	-$1.74M
Free Cash Flow	-$19.61M	-$39.46M	-$58.27M	-$32.93M
Depreciation & Amortisation	$568.00K	$632.00K	$1.13M	$2.35M
Stock-Based Compensation	$7.00M	$8.38M	$13.50M	$9.52M
Investing Cash Flow	-$19.33M	$1.61M	$37.36M	$12.45M
Financing Cash Flow	$900.00K	$40.37M	$3.51M	$14.94M
Net Change in Cash	-$37.52M	$3.97M	-$8.07M	-$3.81M

RCEL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$18.51M	$18.42M	$17.06M	$17.61M	$19.25M	$21.70M
Cost of Revenue	$2.83M	$3.47M	$3.19M	$3.30M	$3.52M	$3.94M
Gross Profit	$15.68M	$14.95M	$13.88M	$14.31M	$15.73M	$17.77M
Research & Development	$6.28M	$5.12M	$3.75M	$5.69M	$5.63M	$5.08M
Selling, General & Admin	$21.22M	$20.98M	$19.28M	$19.03M	$18.90M	$19.54M
Operating Expenses	$27.51M	$26.10M	$23.03M	$24.72M	$24.53M	$24.62M
Operating Income	-$11.83M	-$11.15M	-$9.15M	-$10.41M	-$8.80M	-$6.86M
EBITDA	-$12.10M	-$8.11M	-$11.33M	-$9.69M	-$8.57M	-$5.56M
Pretax Income	-$13.85M	-$9.92M	-$13.17M	-$11.64M	-$10.62M	-$7.63M
Income Tax	$8.00K	$4.00K	$15.00K	-$17.00K	-$11.00K	$33.00K
Net Income	-$13.86M	-$9.92M	-$13.19M	-$11.62M	-$10.61M	-$7.66M
Diluted EPS	-0.53	-0.38	-0.46	-0.38	-0.35	-0.25
Diluted Shares	26.25M	26.37M	28.39M	30.38M	30.54M	30.75M

RCEL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$14.87M	$12.22M	$15.42M	$10.24M	$8.31M	$9.14M
Receivables	$12.15M	$11.65M	$9.04M	$9.11M	$9.90M	$9.87M
Inventory	$8.39M	$7.54M	$7.24M	$6.93M	$6.12M	$5.29M
Current Assets	$47.97M	$36.25M	$41.37M	$35.49M	$31.65M	$28.39M
Total Assets	$69.56M	$58.13M	$63.73M	$56.39M	$51.54M	$47.78M
Current Liabilities	$22.96M	$62.60M	$61.83M	$62.68M	$66.67M	$68.71M
Long-Term Debt	$41.46M	—	—	—	—	—
Total Debt	$44.07M	$44.59M	$44.77M	$46.05M	$48.12M	$48.48M
Total Liabilities	$74.13M	$71.03M	$70.39M	$73.04M	$74.71M	$75.61M
Retained Earnings	-$373.67M	-$383.59M	-$396.78M	-$408.40M	-$419.01M	-$426.68M
Shareholders' Equity	-$4.57M	-$12.89M	-$6.67M	-$16.65M	-$23.17M	-$27.84M
Working Capital	$25.01M	-$26.35M	-$20.46M	-$27.19M	-$35.02M	-$40.32M
Net Debt	$26.59M	$30.00M	$27.03M	$32.74M	$37.83M	$37.52M

RCEL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$10.31M	-$10.23M	-$5.22M	-$5.44M	-$10.07M	-$3.50M
Capital Expenditure	-$234.00K	-$524.00K	-$955.00K	-$26.00K	-$22.00K	-$111.00K
Free Cash Flow	-$10.54M	-$10.75M	-$6.17M	-$5.46M	-$10.09M	-$3.61M
Depreciation & Amortisation	$521.00K	$552.00K	$574.00K	$700.00K	$627.00K	$605.00K
Stock-Based Compensation	$2.69M	$2.67M	$2.78M	$1.37M	$1.10M	$1.99M
Investing Cash Flow	$10.77M	$7.02M	-$5.34M	$11.00K	$2.04M	$3.89M
Financing Cash Flow	$363.00K	$559.00K	$13.77M	$248.00K	$6.10M	$437.00K
Net Change in Cash	$820.00K	-$2.65M	$3.21M	-$5.18M	-$1.93M	$830.00K

Market Snapshot

About

Avita Medical, Inc. is a regenerative medicine company developing and commercializing innovative products for skin restoration. Its flagship RECELL System uses a small skin sample to create a suspension of skin cells that can be applied to burns and other wounds to regenerate skin at the point of care. The technology enables treatment of larger wound areas with minimal donor skin, reducing scarring and improving healing outcomes for burn victims and patients requiring skin reconstruction.